Event Type
Disclosure
Voluntary
Variant
8-K
of this Form 8-K (including Exhibits 99.1 and 99.2) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (t
. Other Events On January 7, 2026, the Company announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD b
. Financial Statements and Exhibits (d) Exhibits 99.1 Press Release issued by Monte Rosa Therapeutics, Inc. dated January 7, 2026. 99.2 MRT-8102 Phase 1 Clinica